A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Czuczman Myron S.; Trneny Marek; Davies Andrew; Rule Simon; Linton Kim M.; Wagner-Johnston Nina; Gascoyne Randy D.; Slack Graham W.; Brousset Pierre; Eberhard David A.; Hernandez-Ilizaliturri Francisco J.; Salles Gilles; Witzig Thomas E.; Zinzani Pier Luigi; Wright George W.; Staudt Louis M.; Yang Yandan; Williams P. Mickey; Lih Chih-Jian; Russo Jacqueline; Thakurta Anjan; Hagner Patrick; Fustier Pierre; Song Dale; Lewis Ian D.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

【24h】

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

机译：2/3个多中心，随机的开放标签研究，用于比较Lenalidomide对调查患者在复发或难治性弥漫性大B细胞淋巴瘤患者中的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: Randomized, multicenter, open-label, phase 2/3 trial investigating lenalidomide versus investigator's choice (IC) in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

机译：目的：随机，多中心，开放标签，2/3试验研究Lenalidomide与调查域的选择（IC）复发/难治性弥漫性大B细胞淋巴瘤（DLBCL）。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research》 |2017年第15期|共11页
作者
Czuczman Myron S.; Trneny Marek; Davies Andrew; Rule Simon; Linton Kim M.; Wagner-Johnston Nina; Gascoyne Randy D.; Slack Graham W.; Brousset Pierre; Eberhard David A.; Hernandez-Ilizaliturri Francisco J.; Salles Gilles; Witzig Thomas E.; Zinzani Pier Luigi; Wright George W.; Staudt Louis M.; Yang Yandan; Williams P. Mickey; Lih Chih-Jian; Russo Jacqueline; Thakurta Anjan; Hagner Patrick; Fustier Pierre; Song Dale; Lewis Ian D.;
展开▼
作者单位

Roswell Pk Canc Inst Buffalo NY 14263 USA;

Charles Univ Hosp Dept Hematol Prague Czech Republic;

Univ Southampton Fac Med Canc Sci Unit Southampton Hants England;

Derriford Hosp Dept Haematol Plymouth Devon England;

Christie Fdn Trust Div Mol &

Clin Canc Sci Manchester Lancs England;

Washington Univ Sch Med Div Oncol St Louis MO USA;

BC Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;

BC Canc Agcy Ctr Lymphoid Canc Vancouver BC Canada;

CHU Purpan Lab Anat Pathol Toulouse France;

Univ N Carolina Dept Pathol Lab Med Chapel Hill NC USA;

Roswell Pk Canc Inst Buffalo NY 14263 USA;

Ctr Hosp Lyon Sud Hos Civils Lyon Hematol Dept Pierre Benite France;

Mayo Clin Dept Lab Med &

Pathol Rochester MN USA;

Univ Bologna Inst Hematol &

Med Oncol Bologna Italy;

NCI Biometr Res Branch Div Canc Treatment &

Diag NIH Bethesda MD 20892 USA;

NCI Lymphoid Malignancies Branch Ctr Canc Res NIH Bethesda MD 20892 USA;

NCI Lymphoid Malignancies Branch Ctr Canc Res NIH Bethesda MD 20892 USA;

NCI Mol Characterizat Lab Frederick Natl Lab Canc Res NIH Frederick MD 21701 USA;

Leidos Biomed Res Inc Mol Characterizat &

Clin Assay Dev Lab Frederick MD USA;

Celgene Corp Summit NJ 07901 USA;

Celgene Corp Summit NJ 07901 USA;

Celgene Corp Summit NJ 07901 USA;

Celgene Corp Boudry Switzerland;

Celgene Corp Summit NJ 07901 USA;

Royal Adelaide Hosp Div Haematol Adelaide SA Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma [J] . Czuczman Myron S., Trneny Marek, Davies Andrew, Clinical cancer research: an official journal of the American Association for Cancer Research . 2017,第15期

机译：2/3个多中心，随机的开放标签研究，用于比较Lenalidomide对调查患者在复发或难治性弥漫性大B细胞淋巴瘤患者中的疗效和安全性
2. A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) [J] . Goy Andre, Ramchandren Radhakrishnan, Ghosh Nilanjan, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：复发性或难治性（R / R）弥漫性大B细胞淋巴瘤（DLBCL）患者中依鲁替尼联合来那度胺和利妥昔单抗的多中心开放标签1b / 2期研究
3. Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations [J] . Landsburg Daniel J., Ramchandren Radhakrishnan, Hafeez Amir, Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：开放标签，第2阶段研究，以评估CUDC-907在复发/难治性弥漫性大型B细胞淋巴瘤患者中的疗效和安全性，包括MYC改变的患者
4. An open-label, multicenter, randomized,comparative, safety, efficacy, cycle control,and quality of life study of CTR 25, Alesse ,and Ortho Tri-Cyclen [C] . Victoria Davis, Brian Hauck, Sheila Dunn, World Congress on Fertility and Sterility . 2004

机译：开放标签，多中心，随机，比较，安全，疗效，循环控制和CTR 25，Alesse和Ortho Tri-Cyclen的生命研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A Phase II Single-Arm Open-Label Multicenter Study to Evaluate the Efficacy and Safety of P276-00 a Cyclin Dependent Kinase Inhibitor in Patients with Relapsed or Refractory Mantle Cell Lymphoma [O] . Ryan D. Cassaday, Andre Goy, Suresh Advani, -1

机译：II期单臂开放标签多中心研究用于评估P276-00（一种细胞周期蛋白依赖性激酶抑制剂）在复发性或难治性套细胞淋巴瘤患者中的疗效和安全性
7. 443TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) [O] . N. Gaspar, Q. Campbell-Hewson, S.S. Bielack, 2020

机译：443TIP一种多中心，开放标签，随机的第二阶段II研究，用于比较Lenvatinib与Ifosfamide和Etoposide的疗效和安全性与儿童，青少年和甜食骨肉中复发或难治性骨肉瘤（Olie; ITCC-082）的青少年

A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅